Collaborations

Collaboration agreement signed with Centocor, Inc. to create improved antibodies

Published in Gene Therapy Weekly, August 18th, 2005

Xencor, Inc., a biotherapeutics company developing protein therapeutics and antibody drugs, announced a collaboration with Centocor, Inc. to create monoclonal antibodies with improved therapeutic efficacy.

Under the terms of the agreement, Xencor's XmAb engineered antibody Fc domains will be used to create antibody drug candidates that Centocor will evaluate against an oncology target. Xencor will receive an upfront payment and is eligible to receive additional license fees, milestones and royalties in the event that Centocor advances candidates into development. Specific financial terms were not disclosed.

Xencor's XmAb engineered Fc domains are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry